DOCSLIB.ORG

EPSIPRANTEL Veterinary—Oral-Local

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EPSIPRANTEL Veterinary—Oral-Local EPSIPRANTEL Veterinary—Oral-Local A commonly used brand name for a veterinary-labeled Chemical name: (±)-2-(Cyclohexylcarbonyl)- product is Cestex. 2,3,6,7,8,12b-hexahydropyrazino[2, 1- {R-4} a][2]benzazepin-4(1H)-one. {R-4} Note: For a listing of dosage forms and brand names by Molecular formula: C20H26N202. country availability, see the Dosage Forms Molecular weight: 326.43.{R-1; 4} {R-1} section(s). Description: A stable, white solid. {R-1} Solubility: Sparingly soluble in water. Category: Anthelmintic. Pharmacology/Pharmacokinetics Indications Mechanism of action/Effect: The mechanism of Note: The text between ELUS and EL describes uses that action of epsiprantel appears to be similar to that of are not included in U.S. product labeling. Text praziquantel, a drug that disrupts the regulation of between ELCAN and EL describes uses that are not calcium and other cations. Tetanic muscle included in Canadian product labeling. contraction and paralysis occurs in the parasite, and {R-8; 10} The ELUS or ELCAN designation may signify a lack the tegument becomes vacuolized. of product availability in the country indicated. Absorption: Minimal absorption occurs in cats and See the Dosage Forms section of this monograph {R-1; 5} to confirm availability. dogs after oral administration. Biotransformation: There is no evidence that Cats and dogs {R-8} Accepted epsiprantel is metabolized. Cestode, gastrointestinal, infection (treatment)— Epsiprantel tablets are indicated in the treatment of Concentrations: Peak plasma concentration— tapeworms, Dipylidium caninum in cats and dogs, Cats: In 83% of cats in one study, the plasma Taenia taeniaeformis in cats, and Taenia pisiformis concentration of epsiprantel was below the level in dogs.{R-1} of detection in all samples taken after an oral dose of 5.5 mg per kg of body weight (mg/kg).{R- 8} Potentially effective When plasma epsiprantel could be measured, the peak concentration was 0.21 mcg/mL at 30 Cestode, gastrointestinal, infection (treatment)—Cats {R-8} ELUS,CAN minutes after administration of the dose. and dogs: There is evidence to suggest that Dogs: 0.13 mcg/mL (range, <0.5–0.36) at 1 hour epsiprantel is effective in the treatment of after an oral dose of 5.5 mg/kg.{R-8} Echinococcus granulosus and Echinococcus multilocularis; however, there are insufficient data to recommend a dosage that can be relied upon to Elimination: Cats and dogs—Because only trace amounts are absorbed, epsiprantel is predominantly clear the infection in all animals treated (Evidence {R-8} {R-9-11}EL eliminated in the feces. Less than 0.1% of the rating: A-1). {R-8} dose is eliminated in the urine in dogs. Chemistry {R-5} Precautions to Consider Chemical group: Pyrazino benzazepine. Reproduction/Pregnancy There is no information on the safety of administering {R-1} epsiprantel to breeding or pregnant animals. Evidence ratings Evidence Quality Evidence Type A Good evidence to support a recommendation for use 1 Species-specific evidence from at least one large randomized and B Moderate evidence to support a recommendation for use controlled trial (RCT) or multiple small RCTs C Insufficient evidence to support a recommendation for use 2 Species-specific evidence from a small RCT, disease models, D Moderate evidence to support a recommendation against use large case studies, pharmacokinetic studies using surrogate E Good evidence to support a recommendation against use endpoints, or evidence from well-designed trials in a different species that is considered appropriate for comparison 3 Dramatic results from either well-designed, species-specific trials without controls, controlled trials without randomization, or small case studies 4 Pharmacokinetic studies without surrogate endpoints or well designed pharmacodynamic studies in healthy animals 5 In vitro studies 6 Opinions of respected authorities on the basis of clinical experience or reports of expert committees © 2008 The United States Pharmacopeial Convention All rights reserved With a single oral dose of 50 mg/kg (18 times the Pediatrics recommended dose):{R-2} Because studies have not been performed in very young Trembling, transient; vomiting animals, the manufacturer’s product labeling does Note: Epsiprantel is highly tolerated in cats. With the not recommend administering epsiprantel to kittens above dose, one of five kittens exhibited signs. or puppies less than 7 weeks of age.{R-1} A single oral dose of 30 mg/kg produced no evidence of toxicity in 7-week old kittens or Drug interactions and/or related problems adult cats.{R-3} A group of six cats tolerated the The following drug interactions and/or related problems administration of 100 mg/kg a day for four days, have been selected on the basis of their potential with no adverse effects reported.{R-1} clinical significance (possible mechanism in Dogs parentheses where appropriate)—not necessarily With an oral dose of 100 to 500 mg/kg a day for inclusive (» = major clinical significance): fourteen days (18 to 91 times the recommended Note: Drug interactions have not been reported with the dose):{R-1; 2} administration of epsiprantel to animals. It was Alkaline phosphatase, increased—with the 500- administered concurrently with mg/kg dose only; lymphocyte count, decreased— diethylcarbamazine citrate, anti-inflammatory females only; proteinuria, slight; total white cell agents, insecticides, and nematocides with no count, decreased—with the 500-mg/kg dose only interactions reported during clinical field Note: Epsiprantel is highly tolerated in dogs. With studies.{R-1} The administration of pyrantel to the above dosage administration, food intake by dogs concurrently with epsiprantel did not affect the dogs was unaffected. Other than isolated the cestocidal efficacy of epsiprantel.{R-6} instances of vomiting by dogs in all dosing groups in this study (10-, 100-, and 500-mg/kg Patient monitoring doses), no adverse physical signs were reported. The following may be especially important in patient No significant effects were described in post- monitoring (other tests may be warranted in some treatment tissue samples for histopathology.{R-2} patients, depending on condition; » = major clinical A single oral dose of 100 mg/kg administered to significance): 7- to 10-week old puppies produced no overt Fecal exam; or signs of toxicity.{R-3} Observation for motile proglottids (reinfection may be noted by eggs or proglottids Treatment of overdose on fecal examination or by observation of motile There is no specific antidote for epsiprantel overdose. If proglottids on the feces or perineal region of the toxicity occurs, recommended treatment consists of animal) the following: • Decrease absorption with early gastric lavage. Side/Adverse Effects • Supportive treatment Note: Side/adverse effects have not been reported with recommended dosing. Client Consultation In providing consultation, consider emphasizing the Overdose following selected information: For more information in cases of overdose or Taking steps to control exposure to intermediate unintentional ingestion, contact the American hosts should be considered in preventing Society for the Prevention of Cruelty to Animals reinfection. For Taenia taeniaeformis, (ASPCA) National Animal Poison Control Center intermediate hosts are mice, rats and other (888-426-4435 or 900-443-0000; a fee may be rodents. For Taenia pisiformis, intermediate hosts required for consultation) and/or the drug are rabbits and other rodents. For prevention of manufacturer. Dipylidium caninum infection, effective flea {R-1} control is important. Clinical effects of overdose The following effects have been selected on the basis of Veterinary Dosing Information their potential clinical significance (possible signs in Diet parentheses where appropriate)—not necessarily Fasting before treatment is not necessary and, therefore, inclusive: is not recommended.{R-1} Kittens Dosing and Dosage Forms © 2008 The United States Pharmacopeial Convention All rights reserved 2 Note: The text between ELUS and EL describes uses not included in U.S. product labeling. Text between Packaging and storage: Store between 15 and 30 °C ELCAN and EL describes uses that are not included (59 and 86 °F),{R-1; 3} unless otherwise specified by in Canadian product labeling. the manufacturer. Store in a tight container. The ELUS or ELCAN designation can signify a lack of Additional information: Keep out of the reach of product availability in the country indicated. See {R-1} also the Strength(s) usually available section for children. each dosage form. Developed: 12/01/08 DOSAGES References 1. Cestex Veterinary Tablets product labeling (Pfizer— Cats and dogs—For Epsiprantel Tablets US), Rev 11/00. Available at www.pfizerah.com. Cestode, gastrointestinal, infection— {R-1} Accessed on September 26, 2008. Cats: Oral, 2.75 mg per kg of body weight. With 2. Freedom of information summary. Cestex ongoing exposure, retreatment may be {R-1; 3} (epsiprantel) tablets. NADA 140-893. Sponsor: necessary. Beecham Laboratories. Approval date: December 1, {R-1} Dogs: Oral, 5.5 mg per kg of body weight. With 1989. Available at www.fda.gov/cvm. Accessed on ongoing exposure, retreatment may be September 26, 2008. {R-1; 3} necessary. 3. Cestex product information (Pfizer—Canada). Note: Cestode, gastrointestinal, infection—ELUS,CANFor Available at www.pfizer.ca. Accessed on September the treatment of Echinococcus species: 26, 2008. Cats: Although the efficacy has not been 4. USP dictionary of USAN and international drug established, one
Load more

Recommended publications
  • Clinical Cysticercosis: Diagnosis and Treatment 11 2
    WHO/FAO/OIE Guidelines for the surveillance, prevention and control of taeniosis/cysticercosis Editor: K.D. Murrell Associate Editors: P. Dorny A. Flisser S. Geerts N.C. Kyvsgaard D.P. McManus T.E. Nash Z.S. Pawlowski • Etiology • Taeniosis in humans • Cysticercosis in animals and humans • Biology and systematics • Epidemiology and geographical distribution • Diagnosis and treatment in humans • Detection in cattle and swine • Surveillance • Prevention • Control • Methods All OIE (World Organisation for Animal Health) publications are protected by international copyright law. Extracts may be copied, reproduced, translated, adapted or published in journals, documents, books, electronic media and any other medium destined for the public, for information, educational or commercial purposes, provided prior written permission has been granted by the OIE. The designations and denominations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the OIE concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. The views expressed in signed articles are solely the responsibility of the authors. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by the OIE in preference to others of a similar nature that are not mentioned. –––––––––– The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations, the World Health Organization or the World Organisation for Animal Health concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Taenia Infections Iowa State University Center for Food Security and Public Health
    Center for Food Security and Public Health Center for Food Security and Public Health Technical Factsheets 5-1-2005 Taenia Infections Iowa State University Center for Food Security and Public Health Follow this and additional works at: http://lib.dr.iastate.edu/cfsph_factsheets Part of the Animal Diseases Commons, and the Veterinary Infectious Diseases Commons Recommended Citation Iowa State University Center for Food Security and Public Health, "Taenia Infections" (2005). Center for Food Security and Public Health Technical Factsheets. 131. http://lib.dr.iastate.edu/cfsph_factsheets/131 This Report is brought to you for free and open access by the Center for Food Security and Public Health at Iowa State University Digital Repository. It has been accepted for inclusion in Center for Food Security and Public Health Technical Factsheets by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Taenia Etiology Taenia spp. are long, segmented, parasitic tapeworms (family Taeniidae, subclass Infections Cestoda). These parasites have an indirect life cycle, cycling between a definitive and an intermediate host. The following Taenia species are zoonotic, with humans serving Taeniasis, as the definitive host, the intermediate host, or both. Non-zoonotic species of Taenia also exist. Cysticercosis, Neurocysticercosis, Taeniasis Coenurosis, The adult tapeworms live in the intestines of the definitive hosts. This infection is Neurocoenurosis called taeniasis. Humans are the definitive hosts for Taenia solium (the pork tapeworm) and T. saginata (the beef tapeworm). Humans are also the definitive hosts for T. asiatica, a newly recognized tapeworm found in Asia. It is currently uncertain Last Updated: May 2005 whether T.
    [Show full text]
  • Cestex ® (Epsiprantel)
    FPO 2D 40027642 ® (epsiprantel) weight; dogs, 2.5 mg/lb of body weight. The following table may be ® used as a guide: Dosage Schedule (epsiprantel) Feline Body Weight Dose Seven weeks old Veterinary Tablets up to 10 lb 12.5 mg 11–20 lb 25.0 mg Cestex (epsiprantel) tablets are indicated for the removal of tapeworms Canine in the cat (Dipylidium caninum and Taenia taeniaeformis) and dog Body Weight Dose (Dipylidium caninum and Taenia pisiformis). Seven weeks old up to 5 lb 12.5 mg CAUTION: Federal law restricts this drug to use by or on the order of 6–10 lb 25.0 mg a licensed veterinarian. 11–20 lb 50.0 mg DESCRIPTION: Cestex tablets are film-coated and contain 12.5 mg, 21–40 lb 100.0 mg 25 mg, 50 mg or 100 mg of epsiprantel per tablet. 41–50 lb 125.0 mg Epsiprantel is an anthelmintic that is active as a single dose against 51–60 lb 150.0 mg the common tapeworms of cats and dogs. Epsiprantel has a molecular 61–80 lb 200.0 mg weight of 326 and is chemically 2-(cyclohexyl-carbonyl)-4-oxo 1,2,3,4, 81–90 lb 225.0 mg 6,7,8,12b-octahydro pyrazino[2,1-a][2]benza-zepine. It is a stable white 91–100 lb 250.0 mg solid which is sparingly soluble in water. Its chemical structure is pre- 101+ lb 2.5 mg/lb, rounding up to next whole sented below. tablet combination Fasting is not necessary or recommended.
    [Show full text]
  • Sheet1 Page 1 a Abamectin Acetazolamide Sodium Adenosine-5-Monophosphate Aklomide Albendazole Alfaxalone Aloe Vera Alphadolone A
    Sheet1 A Abamectin Acetazolamide sodium Adenosine-5-monophosphate Aklomide Albendazole Alfaxalone Aloe vera Alphadolone Acetate Alpha-galactosidase Altrenogest Amikacin and its salts Aminopentamide Aminopyridine Amitraz Amoxicillin Amphomycin Amphotericin B Ampicillin Amprolium Anethole Apramycin Asiaticoside Atipamezole Avoparcin Azaperone B Bambermycin Bemegride Benazepril Benzathine cloxacillin Benzoyl Peroxide Benzydamine Bephenium Bephenium Hydroxynaphthoate Betamethasone Boldenone undecylenate Boswellin Bromelain Bromhexine 2-Bromo-2-nitropan-1, 3 diol Bunamidine Buquinolate Butamisole Butonate Butorphanol Page 1 Sheet1 C Calcium glucoheptonate (calcium glucoheptogluconate) Calcium levulinate Cambendazole Caprylic/Capric Acid Monoesters Carbadox Carbomycin Carfentanil Carnidazole Carnitine Carprofen Cefadroxil Ceftiofur sodium Centella asiatica Cephaloridine Cephapirin Chlorine dioxide Chlormadinone acetate Chlorophene Chlorothiazide Chlorpromazine HCl Choline Salicylate Chondroitin sulfate Clazuril Clenbuterol Clindamycin Clomipramine Clopidol Cloprostenol Clotrimazole Cloxacillin Colistin sulfate Copper calcium edetate Copper glycinate Coumaphos Cromolyn sodium Crystalline Hydroxycobalamin Cyclizine Cyclosporin A Cyprenorphine HCl Cythioate D Decoquinate Demeclocycline (Demethylchlortetracycline) Page 2 Sheet1 Deslorelin Desoxycorticosterone Pivalate Detomidine Diaveridine Dichlorvos Diclazuril Dicloxacillin Didecyl dimethyl ammonium chloride Diethanolamine Diethylcarbamazine Dihydrochlorothiazide Diidohydroxyquin Dimethylglycine
    [Show full text]
  • Simparica Trio
    Simparica Trio and Simparica Satisfaction Guarantee If you or your clients feel that Simparica TrioTM (sarolaner, moxidectin, and pyrantel chewable tablets) or Simparica® (sarolaner) Chewables aren’t providing sufficient protection, please call our medical support team to discuss our Satisfaction Guarantee. We will work with you to ensure that you and your clients are satisfied with the performance of Simparica Trio or Simparica or we will refund the cost of your purchase.* The Simparica Trio and Simparica Satisfaction Guarantee is available to any individual who has purchased Simparica Trio or Simparica from a veterinarian or via a veterinarian’s prescription from a Zoetis approved online distributor.** HEARTWORM DISEASE GUIDELINES (SIMPARICA TRIO ONLY): If any dog determined by a licensed veterinarian to be free of heartworm infection at the onset of treatment with Simparica Trio develops heartworm disease, we will provide reimbursement (up to $1,000 and provide Diroban® (melarsomine dihydrochloride) or provide reasonable acquisition costs of melarsomine dihydrochloride) associated with the diagnosis and treatment of heartworm disease and provide a year’s supply of Simparica Trio or ProHeart® 6 (moxidectin) or ProHeart® 12 (moxidectin). Canine Heartworm Reimbursement Requirements: • Simparica Trio was used, at all times, according to its label directions. • Confirmation of heartworm-positive status by two separate blood samples using at least two different brands of antigen tests are required to document heartworm positive status. – The use of an antigen test will be the standard for determining heartworm status. – Knott’s or any filter test for the detection of microfilariae is nots ufficient evidence for pretreatment heartworm negative status.
    [Show full text]
  • Addendum A: Antiparasitic Drugs Used for Animals
    Addendum A: Antiparasitic Drugs Used for Animals Each product can only be used according to dosages and descriptions given on the leaflet within each package. Table A.1 Selection of drugs against protozoan diseases of dogs and cats (these compounds are not approved in all countries but are often available by import) Dosage (mg/kg Parasites Active compound body weight) Application Isospora species Toltrazuril D: 10.00 1Â per day for 4–5 d; p.o. Toxoplasma gondii Clindamycin D: 12.5 Every 12 h for 2–4 (acute infection) C: 12.5–25 weeks; o. Every 12 h for 2–4 weeks; o. Neospora Clindamycin D: 12.5 2Â per d for 4–8 sp. (systemic + Sulfadiazine/ weeks; o. infection) Trimethoprim Giardia species Fenbendazol D/C: 50.0 1Â per day for 3–5 days; o. Babesia species Imidocarb D: 3–6 Possibly repeat after 12–24 h; s.c. Leishmania species Allopurinol D: 20.0 1Â per day for months up to years; o. Hepatozoon species Imidocarb (I) D: 5.0 (I) + 5.0 (I) 2Â in intervals of + Doxycycline (D) (D) 2 weeks; s.c. plus (D) 2Â per day on 7 days; o. C cat, D dog, d day, kg kilogram, mg milligram, o. orally, s.c. subcutaneously Table A.2 Selection of drugs against nematodes of dogs and cats (unfortunately not effective against a broad spectrum of parasites) Active compounds Trade names Dosage (mg/kg body weight) Application ® Fenbendazole Panacur D: 50.0 for 3 d o. C: 50.0 for 3 d Flubendazole Flubenol® D: 22.0 for 3 d o.
    [Show full text]
  • Selection of New Chemicals to Be Used in Conditioned Aversion for Non-Lethal Predation Control 2
    1 Selection of new chemicals to be used in conditioned aversion for non-lethal predation control 2 3 Jorge Tobajasa,*, Pilar Gómez-Ramíreza,b,c, Pedro María-Mojicab, Isabel Navasb,c, 4 Antonio Juan García-Fernándezb,c, Pablo Ferrerasa, Rafael Mateoa 5 6 aInstituto de Investigación en Recursos Cinegéticos (IREC), CSIC-UCLM-JCCM, Ronda de 7 Toledo No. 12, 13071, Ciudad Real, Spain. 8 bToxicology Area, Department of Health Sciences, Faculty of Veterinary, University of 9 Murcia, Campus de Espinardo, 30100 Murcia, Spain. 10 cToxicology and Risk Assessment Group, Biomedical Research Institute of Murcia (IMIB- 11 Arrixaca), University of Murcia, Campus de Espinardo, 30100 Murcia, Spain. 12 13 *Corresponding author 14 E-mail address: [email protected] (J. Tobajas) 15 1 16 Abstract 17 The use of conditioned food aversion (CFA) can reduce the predation conflict and 18 therefore the incidence of illegal poisoning, which is one of the most important 19 conservation threats for predators and scavengers around the world. CFA is a robust 20 learning paradigm that occurs when animals associate a food with a discomfort 21 induced by a chemical, thereby avoiding that food in subsequent encounters. We 22 reviewed the potential of 167 chemical compounds to be used in CFA, considering 23 effects, margin of safety, accessibility, and detectability. After the review, 15 24 compounds fulfilled the required characteristics, but only five were finally selected to 25 be tested in CFA assays with dogs. Of the tested compounds, thiabendazole, thiram 26 and levamisole caused target food rejection by dogs and reduced the time spent eating 27 during post-conditioning.
    [Show full text]
  • When You See the Signs.
    Global Excellence in Animal Health When you see the signs. Praziquantel Injection Cestocide for Dogs & Cats (praziquantel) Praziquantel Injection (praziquantel) INJECTABLE CESTOCIDE FOR DOGS & CATS 56.8 mg/mL Solution • Veterinary NADA 111-607, Approved by FDA CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. FEATURES • Broad-spectrum cestocide for use in dogs and cats • Available in 10 mL and 50 mL vials • Low toxicity - No toxicity demonstrated in dogs or cats at 5x dosage rates FUNCTIONS • Indicated for the removal of the following canine and/or feline cestodes Dogs: Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus including Echinococcus multilocularis Cats: Taenia taeniaeformis and Dipylidium caninum • Formulated for flexible subcutaneous or intramuscular use in dogs and cats • Safe for use in breeding and pregnant dogs and cats BENEFITS • Provides equivalent effectiveness at less cost • Increased ease of use when treating variable sizes of dogs and cats • Safe for use in breeding and pregnant dogs and cats Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Not intended for use in puppies less than four weeks of age. Not intended for use in kittens less than six weeks of age. Strict hygienic precautions should be taken when handling dogs or feces suspected of harboring E. multilocularis. Infected dogs treated for the first time with Praziquantel Injectable and dogs treated at intervals greater than 28 days may shed eggs
    [Show full text]
  • THE WILD RODENT Akodon Azarae (CRICETIDAE: SIGMODONTINAE
    Mastozoología Neotropical ISSN: 0327-9383 [email protected] Sociedad Argentina para el Estudio de los Mamíferos Argentina Miño, Mariela H.; Rojas Herrera, Elba J.; Notarnicola, Juliana THE WILD RODENT Akodon azarae (CRICETIDAE: SIGMODONTINAE) AS INTERMEDIATE HOST OF Taenia taeniaeformis (CESTODA: CYCLOPHYLLIDEA) ON POULTRY FARMS OF CENTRAL ARGENTINA Mastozoología Neotropical, vol. 20, núm. 2, julio-diciembre, 2013, pp. 407-412 Sociedad Argentina para el Estudio de los Mamíferos Tucumán, Argentina Available in: http://www.redalyc.org/articulo.oa?id=45729294015 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Mastozoología Neotropical, 20(2):407-412, Mendoza, 2013 Copyright ©SAREM, 2013 Versión impresa ISSN 0327-9383 http://www.sarem.org.ar Versión on-line ISSN 1666-0536 Nota THE WILD RODENT Akodon azarae (CRICETIDAE: SIGMODONTINAE) AS INTERMEDIATE HOST OF Taenia taeniaeformis (CESTODA: CYCLOPHYLLIDEA) ON POULTRY FARMS OF CENTRAL ARGENTINA Mariela H. Miño1, Elba J. Rojas Herrera1, and Juliana Notarnicola2 1 Laboratorio de Ecología de Poblaciones, Departamento de Ecología, Genética y Evolución, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires – IEGEBA (UBA-CONICET), Ciudad Universitaria, Pabellón II, 4to piso, C1428EGA Buenos Aires, Argentina [correspondence: Mariela H. Miño <[email protected]>]. 2 Centro de Estudios Parasitológicos y de Vectores CEPAVE (CCT La Plata-CONICET-UNLP), Calle 2 N° 584, 1900 La Plata, Buenos Aires, Argentina. ABSTRACT. This work reports strobilocerci of Taenia taeniaeformis in the rodent Akodon azarae.
    [Show full text]
  • Description and Life-Cycle of Taenia Lynciscapreoli Sp. N. (Cestoda, Cyclophyllidea)
    A peer-reviewed open-access journal ZooKeys 584:Description 1–23 (2016) and life–cycle of Taenia lynciscapreoli sp. n. (Cestoda, Cyclophyllidea) 1 doi: 10.3897/zookeys.584.8171 RESEARCH ARTICLE http://zookeys.pensoft.net Launched to accelerate biodiversity research Description and life-cycle of Taenia lynciscapreoli sp. n. (Cestoda, Cyclophyllidea) Voitto Haukisalmi1, Sergey Konyaev2, Antti Lavikainen3, Marja Isomursu4, Minoru Nakao5 1 Finnish Museum of Natural History Luomus, P.O. Box 17, FI–00014 University of Helsinki, Finland 2 Institute of Systematics and Ecology of Animals SB RAS, 630091, Frunze str. 11, Novosibirsk, Russia 3 Immunobiology Program/Department of Bacteriology and Immunology, Faculty of Medicine, P.O. Box 21, FI–00014 University of Helsinki, Finland 4 Finnish Food Safety Authority Evira, Elektroniikkatie 3, FI– 90590 Oulu, Finland 5 Department of Parasitology, Asahikawa Medical University, Asahikawa, Hokkaido 078–8510, Japan Corresponding author: Voitto Haukisalmi ([email protected]) Academic editor: B. Georgiev | Received 18 February 2016 | Accepted 24 March 2016 | Published 25 April 2016 http://zoobank.org/E381D5EF-73A0-43C3-8630-A017869F1473 Citation: Haukisalmi V, Konyaev S, Lavikainen A, Isomursu M, Nakao M (2016) Description and life-cycle of Taenia lynciscapreoli sp. n. (Cestoda, Cyclophyllidea). ZooKeys 584: 1–23. doi: 10.3897/zookeys.584.8171 Abstract A new species of tapeworm, Taenia lynciscapreoli sp. n. (Cestoda, Cyclophyllidea), is described from the Eurasian lynx (Lynx lynx), the main definitive host, and the roe deer Capreolus( capreolus and C. pygar- gus), the main intermediate hosts, from Finland and Russia (Siberia and the Russian Far East). The new species was found once also in the wolf (Canis lupus) and the Eurasian elk/moose (Alces alces), represent- ing accidental definitive and intermediate hosts, respectively.
    [Show full text]